CRISPR-based Electrochemical Biosensor Detects Disease-related MicroRNAs

With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions.

CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

Recent computational efforts to identify new CRISPR systems uncovered a novel type of RNA targeting enzyme, Cas13. The diverse Cas13 family contains at least four known subtypes, including Cas13a (formerly C2c2), Cas13b, Cas13c, and Cas13d. Cas13a was shown to bind and cleave RNA, protecting bacteria from RNA phages and serving as a powerful platform for RNA manipulation. It was suggested that Cas13a could function as part of a versatile, RNA-guided RNA-targeting CRISPR/Cas system holding great potential for precise, robust, and scalable RNA-guided RNA-targeting applications.

Investigators at the University of Freiburg (Germany) exploited the features of Cas13a by using it to power a microfluidic, integrated electrochemical biosensor for the on‐site detection of microRNAs. An RNA-containing serum sample was placed in the sensor. If it contained the target RNA, this molecule combined with a protein complex in the solution and activated the Cas cleavage enzyme. Following activation, the enzyme cleaved reporter RNAs that were attached to signaling molecules, generating an electrical current, which was measured electrochemically. This change indicated whether the target miRNA was present in the sample. If the target microRNA was not present, no current was generated.

The investigators showed that by employing this unique combination of agents, the quantification of the potential microRNA tumor markers miR‐19b and miR‐20a was achieved without nucleic acid amplification. The system required less than 0.6 microliters of sample, had a readout time of nine minutes, and an overall process time of less than four hours. Furthermore, the feasibility of the biosensor platform to detect miR‐19b in serum samples from children suffering from brain cancer, was demonstrated.

“Our electrochemical biosensor is five to 10 times more sensitive than other applications which use CRISPR/Cas for RNA analysis,” said contributing author Dr. Can Dincer, a research group leader in the department of microsystems engineering at the University of Freiburg. “What is special about our system is that it works without the replication of miRNA, because in that case, specialized devices and chemicals would be required. That makes our system low-cost and considerably faster than other techniques or methods.”

The CRISPR-based biosensor was described in the October 30, 2019, online edition of the journal Advanced Materials.

Related Links:
University of Freiburg